Dovato

DOVATO (dolutegravir/lamivudine) is listed on the Australian Register of Therapeutic Goods (ARTG).

DOVATO (a fixed dose combination of dolutegravir and lamivudine) is indicated for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection in adults and adolescents (from 12 years of age weighing at least 40 kg):

• in antiretroviral treatment-naïve patients with no antiretroviral treatment history who have no known or suspected resistance to either antiretroviral component; or
• to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to the integrase inhibitor class or lamivudine.
  

Resources

For patients:

• Dovato Consumer Medicine Information (PDF)

For HCPs:

• Dovato Product Information (PDF)